September 13, 2021
Article
Adding the investigational agent masitinib to standard frontline docetaxel significantly reduced the risk of disease progression or death in men with metastatic castration-resistant prostate cancer and baseline alkaline phosphatase levels (ALP) of 250 IU/mL or less.
September 11, 2021
Article
A secondary analysis of the phase 3 HERO trial showed that relugolix failed to significantly improve castration resistance–free survival versus standard leuprolide n patients with advanced prostate cancer.
April 01, 2021
Article
Primo Lara, Jr, MD, highlights the multitude of available treatments in frontline renal cell carcinoma, and the need for individualized, multidisciplinary treatment in this setting.
February 12, 2021
Article
The investigational tubulin inhibitor was also safe and well tolerated at continuous daily dosing.